Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.

ABSTRACT:

Background

Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity.

Objective

To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A.

Methods

This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab.

Results

In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 year

SUBMITTER: Bingo M 

PROVIDER: S-EPMC11365868 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature